Phase 1, Open-Label, Randomized, Single-Dose, 5-Way Crossover Pilot Bioavailability Study Comparing Eletriptan Oral Disintegrating Tablet Formulations A And B Administered With Or Without Water To Relpax Commercial Tablets Administered With Water.

Trial Profile

Phase 1, Open-Label, Randomized, Single-Dose, 5-Way Crossover Pilot Bioavailability Study Comparing Eletriptan Oral Disintegrating Tablet Formulations A And B Administered With Or Without Water To Relpax Commercial Tablets Administered With Water.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2010

At a glance

  • Drugs Eletriptan (Primary)
  • Indications Migraine
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 20 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 20 May 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
    • 29 Apr 2009 Additional location identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top